MaxCyte, Inc. General and Administrative Expense
MaxCyte, Inc. (MXCT) reported General and Administrative Expense of $7.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-13
- MaxCyte, Inc. general and administrative expense for the quarter ending 2026-06-30 was $7.26M, a 10.17% decline year-over-year.
- MaxCyte, Inc. general and administrative expense for the quarter ending 2026-03-31 was $5.97M, a 30.03% decline year-over-year.
- MaxCyte, Inc. general and administrative expense for the quarter ending 2025-12-31 was $5.48M, a 23.92% decline year-over-year.
- MaxCyte, Inc. general and administrative expense for the quarter ending 2025-09-30 was $6.03M, a 22.17% decline year-over-year.
- MaxCyte, Inc. general and administrative expense for fiscal 2025 was $28.12M, a 5.31% decline from fiscal 2024.
- MaxCyte, Inc. general and administrative expense for fiscal 2024 was $29.69M, a 1.25% decline from fiscal 2023.
- MaxCyte, Inc. general and administrative expense for fiscal 2023 was $30.07M, a 16.41% increase from fiscal 2022.
- MaxCyte, Inc. general and administrative expense for fiscal 2022 was $25.83M, a 38.30% increase from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 3 month as first filed | General and Administrative Expense 6 month | General and Administrative Expense 6 month as first filed | General and Administrative Expense 9 month | General and Administrative Expense 9 month as first filed | General and Administrative Expense 12 month | General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.26M 10-Q · filed 2026-08-13 | $13.22M 10-Q · filed 2026-08-13 | $18.71M derived: sum of 3 quarters · filed 2026-08-13 | $24.73M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $5.97M 10-Q · filed 2026-05-13 | $11.45M derived: sum of 2 quarters · filed 2026-05-13 | $17.48M derived: sum of 3 quarters · filed 2026-05-13 | $25.56M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $11.51M derived: sum of 2 quarters · filed 2026-03-25 | $19.59M derived: sum of 3 quarters · filed 2026-08-13 | $28.12M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $6.03M 10-Q · filed 2025-11-13 | $14.11M derived: sum of 2 quarters · filed 2026-08-13 | $22.63M 10-Q · filed 2025-11-13 | $29.84M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $8.08M 10-Q · filed 2026-08-13 | $16.61M 10-Q · filed 2026-08-13 | $23.81M derived: sum of 3 quarters · filed 2026-08-13 | $31.56M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $8.53M 10-Q · filed 2026-05-13 | $15.73M derived: sum of 2 quarters · filed 2026-05-13 | $23.48M derived: sum of 3 quarters · filed 2026-05-13 | $31.12M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $14.95M derived: sum of 2 quarters · filed 2026-03-25 | $22.59M derived: sum of 3 quarters · filed 2026-03-25 | $29.69M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $7.75M 10-Q · filed 2025-11-13 | $15.38M derived: sum of 2 quarters · filed 2025-11-13 | $22.49M 10-Q · filed 2025-11-13 | $30.57M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $7.64M 10-Q · filed 2025-08-06 | $14.74M 10-Q · filed 2025-08-06 | $22.83M derived: sum of 3 quarters · filed 2025-08-06 | $29.65M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $7.10M 10-Q · filed 2025-05-08 | $15.19M derived: sum of 2 quarters · filed 2025-05-08 | $22.01M derived: sum of 3 quarters · filed 2025-05-08 | $29.67M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $14.91M derived: sum of 2 quarters · filed 2025-03-11 | $22.57M derived: sum of 3 quarters · filed 2025-03-11 | $30.07M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $6.82M 10-Q · filed 2024-11-06 | $6.82M 10-Q · filed 2023-11-08 | $14.48M derived: sum of 2 quarters · filed 2024-11-06 | $21.98M 10-Q · filed 2024-11-06 | $21.98M 10-Q · filed 2023-11-08 | $27.63M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $7.66M 10-Q · filed 2024-08-06 | $7.66M 10-Q · filed 2023-08-09 | $15.16M 10-Q · filed 2024-08-06 | $15.16M 10-Q · filed 2023-08-09 | $20.81M derived: sum of 3 quarters · filed 2024-08-06 | $27.26M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $7.50M 10-Q · filed 2024-05-07 | $7.50M 10-Q · filed 2023-05-10 | $13.15M derived: sum of 2 quarters · filed 2024-05-07 | $19.59M derived: sum of 3 quarters · filed 2024-05-07 | $26.70M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $12.09M derived: sum of 2 quarters · filed 2024-03-12 | $19.20M derived: sum of 3 quarters · filed 2024-03-12 | $25.83M 10-K · filed 2024-03-12 | $25.83M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $6.44M 10-Q · filed 2023-11-08 | $13.55M derived: sum of 2 quarters · filed 2023-11-08 | $20.18M 10-Q · filed 2023-11-08 | $26.21M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $7.10M 10-Q · filed 2023-08-09 | $13.74M 10-Q · filed 2023-08-09 | $19.77M derived: sum of 3 quarters · filed 2023-08-09 | $25.11M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $6.63M 10-Q · filed 2023-05-10 | $12.66M derived: sum of 2 quarters · filed 2023-05-10 | $18.01M derived: sum of 3 quarters · filed 2023-05-10 | $22.31M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $11.38M derived: sum of 2 quarters · filed 2023-03-15 | $15.68M derived: sum of 3 quarters · filed 2023-03-15 | $18.68M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $5.35M 10-Q · filed 2022-11-09 | $5.65M 10-Q · filed 2021-11-10 | $9.65M derived: sum of 2 quarters · filed 2022-11-09 | $12.65M 10-Q · filed 2022-11-09 | $13.58M 10-Q · filed 2021-11-10 | $14.33M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $4.30M 10-Q · filed 2022-08-10 | $4.62M 10-Q · filed 2021-09-13 | $7.30M 10-Q · filed 2022-08-10 | $7.93M 10-Q · filed 2021-09-13 | $8.98M derived: sum of 3 quarters · filed 2022-08-10 | $11.30M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $3.00M 10-Q · filed 2022-05-09 | $4.68M derived: sum of 2 quarters · filed 2022-05-09 | $7.00M derived: sum of 3 quarters · filed 2022-05-09 | $8.59M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $4.00M derived: sum of 2 quarters · filed 2022-03-22 | $5.59M derived: sum of 3 quarters · filed 2022-03-22 | $7.37M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $2.31M 10-Q · filed 2021-11-10 | $3.91M derived: sum of 2 quarters · filed 2021-11-10 | $5.68M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $1.59M 10-Q · filed 2021-09-13 | $3.37M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $5.56M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |